



**FOR IMMEDIATE RELEASE**

CONTACT: Michael Krampe  
(770) 751-2211  
michael.krampe@siemens.com

Steve Bender  
(865) 719-9840  
stevenbender@charter.net

## **BIND BIOSCIENCES TO INSTALL FIRST SIEMENS SIMATIC® PCS 7 LAB PROCESS CONTROL SYSTEM IN THE U.S.**

ATLANTA, March. 17, 2009 – Siemens Energy & Automation, Inc. announced today that BIND Biosciences, Inc., Cambridge, Mass., has selected Simatic® PCS 7 Lab hardware and software to help its scientists manage pre- and post-clinical experimental data.

BIND Biosciences develops targeted therapeutics based upon their novel polymeric nanoparticle drug delivery technology platform. It is the first company in the United States to install the PCS 7 Lab hardware and software.

With startup services provided by system integrator Optimization Technology, Inc., the phased automation implementation will help BIND Biosciences drive process development as well as monitor and control manufacturing operations.

“The flexibility and expandability of the PCS 7 Lab system will allow us to grow economically and efficiently through all three phases of the implementation,” said Jeff Hrkach, BIND Biosciences Vice President of Pharmaceutical Sciences. “The system has all the tools we need to collect and manage our data as well as protect our intellectual property.”

The PCS 7 Lab configuration, designed for laboratory and process development research and development applications, is based on Siemens Simatic PCS 7 Box. The UL certified system includes a preinstalled rack of I/O modules that can be easily reconfigured to fit any size or type of laboratory environment.

“This partnership with BIND gives Siemens the opportunity to help BIND bring drugs to market faster, “ said Glenn Restivo, Siemens Life Sciences Industry Manager. “We adhere to the Design of Experiment and Quality by Design philosophies that build

quality into every step of the process – from laboratory experimentation through every phase of manufacturing.”

The implementation phase of the PCS 7 project is underway and focuses on basic experimentation and data collection. A second phase is under consideration for cataloging and organizing experimental data. Phase three, also under consideration, will include Siemens Sipat for Process Analytical Technology (PAT), Interspec for specification management and the R&D Suite for Electronic Lab Notebook (ELN).

### **About Siemens:**

Siemens Energy & Automation, Inc. is one of Siemens' operating companies in the U.S. Headquartered in the Atlanta suburb of Alpharetta, Ga., Siemens Energy & Automation, Inc. manufactures and markets one of the world's broadest ranges of electrical and electronic products, systems and services to industrial and construction market customers. Its technologies range from circuit protection and energy management systems to process control, industrial software and totally integrated automation solutions. The company also has expertise in systems integration, technical services and turnkey industrial systems. For more information: [www.sea.siemens.com](http://www.sea.siemens.com).

Siemens AG (NYSE: SI) is a global powerhouse in electronics and electrical engineering, and operates in the industry, energy and healthcare sectors. For more than 160 years, Siemens has built a reputation for leading-edge innovation and the quality of its products, services and solutions. With 428,000 employees in 190 countries, Siemens reported worldwide sales of \$116.6 billion in fiscal 2008. With its U.S. corporate headquarters in New York City, Siemens in the USA reported sales of \$22.4 billion and employs approximately 69,000 people throughout all 50 states and Puerto Rico. For more information on Siemens in the United States, visit [www.usa.siemens.com](http://www.usa.siemens.com).

###